Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab
NCT00319839
Terminated
Primary Objective: To assess the overall response rate (complete and partial response) to Abraxane in patients with recurrent or metastatic head and neck cancer with the addition of Cetuximab on disease progression. Approximately 40,000 new cases of head and neck cancer are diagnosed annually in the United States (Jemal et al, 2003), and over 30% of these patients are expected to die of their malignancy. Squamous cell carcinoma accounts for more than 90% of head and neck cancer cases. Although... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2018
Locations: Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Head and Neck Cancer
Register for Updates
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
NCT01677559
Completed
This phase I trial studies the side effects and the best dose of MLN8237 (alisertib) when given together with paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with solid malignancies that are metastatic or cannot be removed by surgery. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as nab-paclitaxel work by killing the cells or by stopping them from dividing. Giving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2018
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Adenocarcinoma, Pancreatic Neoplasms
Register for Updates
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT00553462
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Erlotinib may make tumor cells more sensitive to radiation therapy. Giving carboplatin and paclitaxel albumin-stabilized nanoparticle formulation together with radiation therapy and erlotinib may k... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2018
Locations: East Bay Radiation Oncology Center, Castro Valley, California +98 locations
Conditions: Lung Cancer
Register for Updates
Abraxane and Alimta in Advanced Solid Tumors
NCT00470548
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel albumin-stabilized nanoparticle formulation together with pemetrexed may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2018
Locations: University of California Davis Cancer Center, Sacramento, California
Conditions: Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00499252
Completed
This phase II trial is studying the side effects and how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Gender:
FEMALE
Ages:
All
Trial Updated:
12/14/2017
Locations: Colorado Gynecologic Oncology Group, Aurora, Colorado +19 locations
Conditions: Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Register for Updates
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
NCT00093795
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/11/2017
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +11 locations
Conditions: Breast Cancer
Register for Updates
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
NCT00821964
Completed
This phase II trial is studying the side effects of giving topical imiquimod together with Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) to see how well it works in treating patients with advanced breast cancer. Biological therapies, such as imiquimod, may stimulate the immune system to kill tumor cells. Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2017
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Male Breast Cancer, Recurrent Breast Cancer, Skin Metastases, Stage IV Breast Cancer
Register for Updates
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer
NCT02172846
Completed
This phase I trial studies the side effects and best dose of hypofractionated proton beam radiation therapy when given together with paclitaxel and carboplatin in treating patients with stage II-III non-small cell lung cancer. Proton beam radiation therapy is a type of radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. Giving proton beam radiation therapy at higher doses over fewer days (hypofractionation) may improve local control of the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2017
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
NCT00585052
Terminated
The purpose of this study is to find out if the treatment combination of paclitaxel and lovastatin is more effective than the currently available chemotherapy for refractory or relapsed ovarian cancer. This research is being done to improve on currently available chemotherapy for ovarian cancer.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
12/05/2017
Locations: Holden Comprehensive Cancer Center, Iowa City, Iowa
Conditions: Ovarian Cancer
Register for Updates
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00331422
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving chemotherapy drugs before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin before surgery works in treating patients with advanced ovarian epithelial canc... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/03/2017
Locations: University of Minnesota Cancer Center, Minneapolis, Minnesota
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
NCT00433966
Completed
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing a primary angioplasty strategy. 2. To establish the safety and efficacy of the slow rate release paclitaxel-eluting TAXUS™ stent compared to an otherwise identical uncoated bare metal EXPRESS2™ stent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/30/2017
Locations: LeBauer CV Research Foundation, Greensboro, North Carolina
Conditions: Myocardial Infarction
Register for Updates
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00023673
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them with specialized radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the effectiveness of radiation therapy combined with paclitaxel and carboplatin in treating patients who have stage III non... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2017
Locations: Mobile Infirmary Medical Center, Mobile, Alabama +40 locations
Conditions: Lung Cancer
Register for Updates